Cardiovascular Drugs MGR 2017
July 2017
125
About the Report
About the Report
Cardiovascular disorders drug market covers the drugs used to treat conditions that affect heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anticoagulants such as Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Apixaban (Eliquis), Heparin, and Warfarin.
The global cardiovascular disorders drugs market was estimated to be around $126 billion as of 2016. The cardiovascular disorders drugs market made up around 12% of the overall pharmaceuticals market in 2016. The cardiovascular disorders drugs market was the third largest market, following the pharmaceutical drugs and biologics market in the global pharmaceutical market in 2016.
Development Of Personalized Medicine For The Treatment Of Cardiovascular Diseases
Innovation of gene testing technologies for the development of personalized medicine for cardiovascular diseases is one of the major trend in the market. Due to the reduction in the cost of gene testing, patients can screen for their predisposition for specific cardiovascular diseases. Gene testing helps in development of personalized pharmacogenomic agents and improved patient monitoring efforts and detect them before an onset of acute care episodes.
The Cardiovascular Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The Cardiovascular Drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Anti-Hypertensive, Hypolipidemics, Anti Thrombotics, Others (Congestive Heart Failure, Anti- Arrythmic And Anti-Anginal Drugs)
Companies Mentioned: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Products
Products
Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
Companies
Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG
Table of Contents
Table of Contents
1. Cardiovascular Drugs Market Characteristics;
2. Cardiovascular Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Cardiovascular Drugs Market Customer Information;
5. Cardiovascular Drugs Market Segmentation;
5.1. Global Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 5.2. Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Cardiovascular Drugs Market Trends And Strategies;
6. Cardiovascular Drugs Market Regional And Country Analysis;
6.1. Global Cardiovascular Drugs Market, 2016, By Region; 6.2. Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Cardiovascular Drugs Market, 2016, By Country; 6.4. Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Cardiovascular Drugs Market Comparison With Macro Economic Factors;
7.1. Cardiovascular Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Cardiovascular Drugs Expenditure, Global;
8. Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Cardiovascular Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Cardiovascular Drugs Expenditure, By Country;
9. Cardiovascular Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Cardiovascular Drugs Market;
10.1.1. Asia-Pacific Cardiovascular Drugs Market Overview; 10.1.2. Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.2. Asia-Pacific Cardiovascular Drugs Market: Country Analysis; 10.3. China Cardiovascular Drugs Market; 10.3.1. China Cardiovascular Drugs Market Overview; 10.3.2. China Cardiovascular Drugs Historic Market, 2012-2016; 10.3.3. China Cardiovascular Drugs Forecast Market, 2016-2020; 10.3.4. China Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.3.5. China Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.4. India Cardiovascular Drugs Market; 10.4.1. India Cardiovascular Drugs Market Overview; 10.4.2. India Cardiovascular Drugs Historic Market, 2012-2016; 10.4.3. India Cardiovascular Drugs Forecast Market, 2016-2020; 10.4.4. India Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.4.5. India Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.5. Japan Cardiovascular Drugs Market; 10.5.1. Japan Cardiovascular Drugs Market Overview; 10.5.2. Japan Cardiovascular Drugs Historic Market, 2012-2016; 10.5.3. Japan Cardiovascular Drugs Forecast Market, 2016-2020; 10.5.4. Japan Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.5.5. Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.6. Australia Cardiovascular Drugs Market; 10.6.1. Australia Cardiovascular Drugs Historic Market, 2012-2016; 10.6.2. Australia Cardiovascular Drugs Forecast Market, 2016-2020; 10.6.3. Australia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.6.4. Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;
11. Western Europe Cardiovascular Drugs Market;
11.1.1. Western Europe Cardiovascular Drugs Market Overview; 11.1.2. Western Europe Cardiovascular Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Cardiovascular Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.2. Western Europe Cardiovascular Drugs Market: Country Analysis; 11.3. UK Cardiovascular Drugs Market; 11.3.1. UK Cardiovascular Drugs Market Overview; 11.3.2. UK Cardiovascular Drugs Historic Market, 2012-2016; 11.3.3. UK Cardiovascular Drugs Forecast Market, 2016-2020; 11.3.4. UK Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.3.5. UK Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.4. Germany Cardiovascular Drugs Market; 11.4.1. Germany Cardiovascular Drugs Historic Market, 2012-2016; 11.4.2. Germany Cardiovascular Drugs Forecast Market, 2016-2020; 11.4.3. Germany Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.4.4 Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.5 France Cardiovascular Drugs Market; 11.5.1 France Cardiovascular Drugs Historic Market, 2012-2016; 11.5.2 France Cardiovascular Drugs Forecast Market, 2016-2020; 11.5.3 France Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.5.4 France Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.6. Italy Cardiovascular Drugs Market; 11.6.1. Italy Cardiovascular Drugs Historic Market, 2012-2016; 11.6.2. Italy Cardiovascular Drugs Forecast Market, 2016-2020; 11.6.3. Italy Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.6.4. Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.7. Spain Cardiovascular Drugs Market; 11.7.1. Spain Cardiovascular Drugs Historic Market, 2012-2016; 11.7.2. Spain Cardiovascular Drugs Forecast Market, 2016-2020; 11.7.3. Spain Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.7.4. Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;
12. Eastern Europe Cardiovascular Drugs Market;
12.1.1. Eastern Europe Cardiovascular Drugs Market Overview; 12.1.2. Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.2. Eastern Europe Cardiovascular Drugs Market: Country Analysis; 12.3. Russia Cardiovascular Drugs Market; 12.3.1. Russia Cardiovascular Drugs Historic Market, 2012-2016; 12.3.2. Russia Cardiovascular Drugs Forecast Market, 2016-2020; 12.3.3. Russia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.3.4. Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;
13. North America Cardiovascular Drugs Market;
13.1.1. North America Cardiovascular Drugs Market Overview; 13.1.2. North America Cardiovascular Drugs Historic Market, 2012-2016; 13.1.3. North America Cardiovascular Drugs Forecast Market, 2016-2020; 13.1.4. North America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.2. North America Cardiovascular Drugs Market: Country Analysis; 13.3. USA Cardiovascular Drugs Market; 13.3.1. USA Cardiovascular Drugs Historic Market, 2012-2016; 13.3.2. USA Cardiovascular Drugs Forecast Market, 2016-2020; 13.3.3 USA Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.3.4. USA Cardiovascular Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;
14. South America Cardiovascular Drugs Market;
14.1.1. South America Cardiovascular Drugs Market Overview; 14.1.2. South America Cardiovascular Drugs Historic Market, 2012-2016; 14.1.3. South America Cardiovascular Drugs Forecast Market, 2016-2020; 14.1.4. South America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.2. South America Cardiovascular Drugs Market: Country Analysis; 14.3. Brazil Cardiovascular Drugs Market; 14.3.1. Brazil Cardiovascular Drugs Historic Market, 2012-2016; 14.3.2. Brazil Cardiovascular Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.3.4. Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;
15. Middle East Cardiovascular Drugs Market;
15.1.1. Middle East Cardiovascular Drugs Market Overview; 15.1.2. Middle East Cardiovascular Drugs Historic Market, 2012-2016; 15.1.3. Middle East Cardiovascular Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
16. Africa Cardiovascular Drugs Market;
16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.2. Africa Cardiovascular Drugs Historic Market, 2012-2016; 16.1.3. Africa Cardiovascular Drugs Forecast Market, 2016-2020; 16.1.4. Africa Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
17. Cardiovascular Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Bristol-Myers Squibb Company; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Abbott Laboratories Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Astrazeneca Plc; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Bayer Ag; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Novartis Ag; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Cardiovascular Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5 Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List of Figure
Table 1: Global Cardiovascular Drugs Historic Market Growth
Table 2: Global Cardiovascular Drugs Forecast Market Growth
Table 3: Cardiovascular Drugs Market Segmentation
Table 4: Global Cardiovascular Drugs Market, 2016, By Segment
Table 5: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Cardiovascular Drugs Market, 2016, By Region
Table 7: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 8: Cardiovascular Drugs Market, 2016, By Country
Table 9: Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 10: Global Pharmaceutical Market Segments, 2016, By Region
Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Table 12: Global Pharmaceutical Market Segments, 2016, By Country
Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Table 14: Cardiovascular Drugs Market Size, Percentage Of GDP, Global
Table 15: Per Capita Average Cardiovascular Drugs Expenditure, Global
Table 16: Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries
Table 17: Cardiovascular Drugs Market Size, Percentage Of GDP, By Country
Table 18: Per Capita Average Cardiovascular Drugs Expenditure, By Country
Table 19: Global Number Of Pharmacists, 2016, By Country
Table 20: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 21: Global Number Of Pharma Enterprises, 2016, By Country
Table 22: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 23: Global Average Spending On R&D/Product Development, 2016, By Country
Table 24: Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 26: Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 27: Prevalent Cases Of Hypertension, 2014, By Country
Table 28: Prevalent Cases Of Parkinsons Disease, 2014, By Country
Table 29: Global Number Of General Practitioners 2016, By Country
Table 30: Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Table 31: Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016
Table 32: Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020
Table 33: Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment
Table 34: China Cardiovascular Drugs Historic Market, 2012-2016
Table 35: China Cardiovascular Drugs Forecast Market, 2016-2020
Table 36: China Cardiovascular Drugs Market, 2016, By Segment
Table 37: China Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 38: China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 39: India Cardiovascular Drugs Historic Market, 2012-2016
Table 40: India Cardiovascular Drugs Forecast Market, 2016-2020
Table 41: India Cardiovascular Drugs Market, 2016, By Segment
Table 42: India Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 43: India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 44: Japan Cardiovascular Drugs Historic Market, 2012-2016
Table 45: Japan Cardiovascular Drugs Forecast Market, 2016-2020
Table 46: Japan Cardiovascular Drugs Market, 2016, By Segment
Table 47: Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 48: Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 49: Australia Cardiovascular Drugs Historic Market, 2012-2016
Table 50: Australia Cardiovascular Drugs Forecast Market, 2016-2020
Table 51: Australia Cardiovascular Drugs Market, 2016, By Segment
Table 52: Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 53: Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 54: Western Europe Cardiovascular Drugs Historic Market, 2012-2016
Table 55: Western Europe Cardiovascular Drugs Forecast Market, 2016-2020
Table 56: Western Europe Cardiovascular Drugs Market, 2016, By Segment
Table 57: UK Cardiovascular Drugs Historic Market, 2012-2016
Table 58: UK Cardiovascular Drugs Forecast Market, 2016-2020
Table 59: UK Cardiovascular Drugs Market, 2016, By Segment
Table 60: UK Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 61: UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 62: Germany Cardiovascular Drugs Historic Market, 2012-2016
Table 63: Germany Cardiovascular Drugs Forecast Market, 2016-2020
Table 64: Germany Cardiovascular Drugs Market, 2016, By Segment
Table 65: Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 66: Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 67: France Cardiovascular Drugs Historic Market, 2012-2016
Table 68: France Cardiovascular Drugs Forecast Market, 2016-2020
Table 69: France Cardiovascular Drugs Market, 2016, By Segment
Table 70: France Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 71: France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 72: Italy Cardiovascular Drugs Historic Market, 2012-2016
Table 73: Italy Cardiovascular Drugs Forecast Market, 2016-2020
Table 74: Italy Cardiovascular Drugs Market, 2016, By Segment
Table 75: Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 76: Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 77: Spain Cardiovascular Drugs Historic Market, 2012-2016
Table 78: Spain Cardiovascular Drugs Forecast Market, 2016-2020
Table 79: Spain Cardiovascular Drugs Market, 2016, By Segment
Table 80: Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 81: Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 82: Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016
Table 83: Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020
Table 84: Eastern Europe Cardiovascular Drugs Market, 2016, By Segment
Table 85: Russia Cardiovascular Drugs Historic Market, 2012-2016
Table 86: Russia Cardiovascular Drugs Forecast Market, 2016-2020
Table 87: Russia Cardiovascular Drugs Market, 2016, By Segment
Table 88: Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 89: Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 90: North America Cardiovascular Drugs Historic Market, 2012-2016
Table 91: North America Cardiovascular Drugs Forecast Market, 2016-2020
Table 92: North America Cardiovascular Drugs Market, 2016, By Segment
Table 93: USA Cardiovascular Drugs Historic Market, 2012-2016
Table 94: USA Cardiovascular Drugs Forecast Market, 2016-2020
Table 95: USA Cardiovascular Drugs Market, 2016, By Segment
Table 96: USA Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 97: USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 98: South America Cardiovascular Drugs Historic Market, 2012-2016
Table 99: South America Cardiovascular Drugs Forecast Market, 2016-2020
Table 100: South America Cardiovascular Drugs Market, 2016, By Segment
Table 101: Brazil Cardiovascular Drugs Historic Market, 2012-2016
Table 102: Brazil Cardiovascular Drugs Forecast Market, 2016-2020
Table 103: Brazil Cardiovascular Drugs Market, 2016, By Segment
Table 104: Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020
Table 105: Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Table 106: Middle East Cardiovascular Drugs Historic Market, 2012-2016
Table 107: Middle East Cardiovascular Drugs Forecast Market, 2016-2020
Table 108: Middle East Cardiovascular Drugs Market, 2016, By Segment
Table 109: Africa Cardiovascular Drugs Historic Market, 2012-2016
Table 110: Africa Cardiovascular Drugs Forecast Market, 2016-2020
Table 111: Africa Cardiovascular Drugs Market, 2016, By Segment
Table 112: Bristol-Myers Squibb Company Financial Performance
Table 113: Abbott Laboratories Inc. Financial Performance
Table 114: Astrazeneca Plc Financial Performance
Table 115: Bayer AG Financial Performance
Table 116: Novartis AG Financial Performance
Table 117: Pharmaceutical Drugs Market Historic Growth
Table 118: Pharmaceutical Drugs Market Forecast Growth
Table 119: Global Pharmaceutical Drugs Market, 2016, By Region
Table 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 121: Pharmaceutical Drugs Market, 2016, By Country
Table 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Table 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Table 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Table 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Table 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Table 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Table 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Table 130: Pharmaceuticals Industry Financial Margins
List of Table
Figure 1: Global Cardiovascular Drugs Historic Market Growth
Figure 2: Global Cardiovascular Drugs Forecast Market Growth
Figure 3: Cardiovascular Drugs Market Segmentation
Figure 4: Global Cardiovascular Drugs Market, 2016, By Segment
Figure 5: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Cardiovascular Drugs Market, 2016, By Region
Figure 7: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 8: Cardiovascular Drugs Market, 2016, By Country
Figure 9: Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 10: Global Pharmaceutical Market Segments, 2016, By Region
Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Figure 12: Global Pharmaceutical Market Segments, 2016, By Country
Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Figure 14: Cardiovascular Drugs Market Size, Percentage Of GDP, Global
Figure 15: Per Capita Average Cardiovascular Drugs Expenditure, Global
Figure 16: Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 17: Cardiovascular Drugs Market Size, Percentage Of GDP, By Country
Figure 18: Per Capita Average Cardiovascular Drugs Expenditure, By Country
Figure 19: Global Number Of Pharmacists, 2016, By Country
Figure 20: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 21: Global Number Of Pharma Enterprises, 2016, By Country
Figure 22: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 24: Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 26: Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 27: Prevalent Cases Of Hypertension, 2014, By Country
Figure 28: Prevalent Cases Of Parkinsons Disease, 2014, By Country
Figure 29: Global Number Of General Practitioners 2016, By Country
Figure 30: Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Figure 31: Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016
Figure 32: Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020
Figure 33: Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment
Figure 34: China Cardiovascular Drugs Historic Market, 2012-2016
Figure 35: China Cardiovascular Drugs Forecast Market, 2016-2020
Figure 36: China Cardiovascular Drugs Market, 2016, By Segment
Figure 37: China Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 38: China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 39: India Cardiovascular Drugs Historic Market, 2012-2016
Figure 40: India Cardiovascular Drugs Forecast Market, 2016-2020
Figure 41: India Cardiovascular Drugs Market, 2016, By Segment
Figure 42: India Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 43: India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 44: Japan Cardiovascular Drugs Historic Market, 2012-2016
Figure 45: Japan Cardiovascular Drugs Forecast Market, 2016-2020
Figure 46: Japan Cardiovascular Drugs Market, 2016, By Segment
Figure 47: Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 48: Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 49: Australia Cardiovascular Drugs Historic Market, 2012-2016
Figure 50: Australia Cardiovascular Drugs Forecast Market, 2016-2020
Figure 51: Australia Cardiovascular Drugs Market, 2016, By Segment
Figure 52: Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 53: Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 54: Western Europe Cardiovascular Drugs Historic Market, 2012-2016
Figure 55: Western Europe Cardiovascular Drugs Forecast Market, 2016-2020
Figure 56: Western Europe Cardiovascular Drugs Market, 2016, By Segment
Figure 57: UK Cardiovascular Drugs Historic Market, 2012-2016
Figure 58: UK Cardiovascular Drugs Forecast Market, 2016-2020
Figure 59: UK Cardiovascular Drugs Market, 2016, By Segment
Figure 60: UK Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 61: UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 62: Germany Cardiovascular Drugs Historic Market, 2012-2016
Figure 63: Germany Cardiovascular Drugs Forecast Market, 2016-2020
Figure 64: Germany Cardiovascular Drugs Market, 2016, By Segment
Figure 65: Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 66: Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 67: France Cardiovascular Drugs Historic Market, 2012-2016
Figure 68: France Cardiovascular Drugs Forecast Market, 2016-2020
Figure 69: France Cardiovascular Drugs Market, 2016, By Segment
Figure 70: France Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 71: France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 72: Italy Cardiovascular Drugs Historic Market, 2012-2016
Figure 73: Italy Cardiovascular Drugs Forecast Market, 2016-2020
Figure 74: Italy Cardiovascular Drugs Market, 2016, By Segment
Figure 75: Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 76: Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 77: Spain Cardiovascular Drugs Historic Market, 2012-2016
Figure 78: Spain Cardiovascular Drugs Forecast Market, 2016-2020
Figure 79: Spain Cardiovascular Drugs Market, 2016, By Segment
Figure 80: Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 81: Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 82: Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016
Figure 83: Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020
Figure 84: Eastern Europe Cardiovascular Drugs Market, 2016, By Segment
Figure 85: Russia Cardiovascular Drugs Historic Market, 2012-2016
Figure 86: Russia Cardiovascular Drugs Forecast Market, 2016-2020
Figure 87: Russia Cardiovascular Drugs Market, 2016, By Segment
Figure 88: Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 89: Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 90: North America Cardiovascular Drugs Historic Market, 2012-2016
Figure 91: North America Cardiovascular Drugs Forecast Market, 2016-2020
Figure 92: North America Cardiovascular Drugs Market, 2016, By Segment
Figure 93: USA Cardiovascular Drugs Historic Market, 2012-2016
Figure 94: USA Cardiovascular Drugs Forecast Market, 2016-2020
Figure 95: USA Cardiovascular Drugs Market, 2016, By Segment
Figure 96: USA Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 97: USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 98: South America Cardiovascular Drugs Historic Market, 2012-2016
Figure 99: South America Cardiovascular Drugs Forecast Market, 2016-2020
Figure 100: South America Cardiovascular Drugs Market, 2016, By Segment
Figure 101: Brazil Cardiovascular Drugs Historic Market, 2012-2016
Figure 102: Brazil Cardiovascular Drugs Forecast Market, 2016-2020
Figure 103: Brazil Cardiovascular Drugs Market, 2016, By Segment
Figure 104: Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020
Figure 105: Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020
Figure 106: Middle East Cardiovascular Drugs Historic Market, 2012-2016
Figure 107: Middle East Cardiovascular Drugs Forecast Market, 2016-2020
Figure 108: Middle East Cardiovascular Drugs Market, 2016, By Segment
Figure 109: Africa Cardiovascular Drugs Historic Market, 2012-2016
Figure 110: Africa Cardiovascular Drugs Forecast Market, 2016-2020
Figure 111: Africa Cardiovascular Drugs Market, 2016, By Segment
Figure 112: Bristol-Myers Squibb Company Financial Performance
Figure 113: Abbott Laboratories Inc. Financial Performance
Figure 114: Astrazeneca Plc Financial Performance
Figure 115: Bayer AG Financial Performance
Figure 116: Novartis AG Financial Performance
Figure 117: Pharmaceutical Drugs Market Historic Growth
Figure 118: Pharmaceutical Drugs Market Forecast Growth
Figure 119: Global Pharmaceutical Drugs Market, 2016, By Region
Figure 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 121: Pharmaceutical Drugs Market, 2016, By Country
Figure 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Figure 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Figure 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Figure 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Figure 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Figure 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Figure 130: Pharmaceuticals Industry Financial Margins
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.